Expression of botulinum toxin binding sites in Xenopus oocytes

被引:13
作者
Bakry, NM
Kamata, Y
Simpson, LL
机构
[1] THOMAS JEFFERSON UNIV, JEFFERSON MED COLL, DEPT MED, PHILADELPHIA, PA 19107 USA
[2] THOMAS JEFFERSON UNIV, JEFFERSON MED COLL, DEPT BIOCHEM & MOL PHARMACOL, PHILADELPHIA, PA 19107 USA
[3] UNIV OSAKA PREFECTURE, COLL AGR, DEPT VET SCI, SAKAI, OSAKA 591, JAPAN
关键词
D O I
10.1128/IAI.65.6.2225-2232.1997
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The binding of iodinated botulinum toxin type B to nerve membranes was studied by using rat and mouse preparations, The toxin was examined both in the single-chain and in the proteolytically processed dichain form, and binding sites both in the spinal cord and in various brain regions were assayed, Rat and mouse brains possessed specific binding sites for botulinum toxin type B. The average K-d values for the various rat and mouse membrane preparations examined were 4.2 +/- 0.7 nM and 3.7 +/- 0.9 nM, respectively. The average B-max values for the same tissue preparations were 7.3 +/- 0.7 pmol/mg of protein and 7.5 +/- 1.9 pmol/mg protein, respectively. The binding of botulinum toxin type B to rat brain membranes was not antagonized by a polyclonal antibody against the cytosolic domain of synaptotagmin 1 or by a monoclonal antibody directed against the luminal domain of synaptotagmin 1. In addition, these antibodies did not protect the mouse phrenic nerve-hemidiaphragm from toxin-induced neuromuscular blockade, Extraction of whole-brain mRNA and injection into Xenopus oocytes led to expression of binding sites for botulinum toxin. Extraction and injection of cerebellar mRNA led to expression of a higher density of binding sites. The number of binding sites was not diminished when oocytes were pretreated, with antibodies against the cytosolic and luminal domains of synaptotagmin 1, These findings are likely to aid in the isolation, characterization, and reconstitution of toxin binding sites.
引用
收藏
页码:2225 / 2232
页数:8
相关论文
共 37 条
[1]  
BAKRY N, 1991, J PHARMACOL EXP THER, V258, P613
[2]  
BAKRY N, 1991, J PHARMACOL EXP THER, V258, P830
[3]  
BINZ T, 1994, J BIOL CHEM, V269, P1617
[4]   INTERACTION OF I-125 LABELED BOTULINUM NEUROTOXINS WITH NERVE-TERMINALS .1. ULTRASTRUCTURAL AUTORADIOGRAPHIC LOCALIZATION AND QUANTITATION OF DISTINCT MEMBRANE ACCEPTORS FOR TYPE-A AND TYPE-B ON MOTOR NERVES [J].
BLACK, JD ;
DOLLY, JO .
JOURNAL OF CELL BIOLOGY, 1986, 103 (02) :521-534
[5]   INTERACTION OF I-125 LABELED BOTULINUM NEUROTOXINS WITH NERVE-TERMINALS .2. AUTORADIOGRAPHIC EVIDENCE FOR ITS UPTAKE INTO MOTOR NERVES BY ACCEPTOR-MEDIATED ENDOCYTOSIS [J].
BLACK, JD ;
DOLLY, JO .
JOURNAL OF CELL BIOLOGY, 1986, 103 (02) :535-544
[6]   BOTULINUM NEUROTOXIN-A SELECTIVELY CLEAVES THE SYNAPTIC PROTEIN SNAP-25 [J].
BLASI, J ;
CHAPMAN, ER ;
LINK, E ;
BINZ, T ;
YAMASAKI, S ;
DECAMILLI, P ;
SUDHOF, TC ;
NIEMANN, H ;
JAHN, R .
NATURE, 1993, 365 (6442) :160-163
[7]  
BLASI J, 1993, EMBO J, V12, P4821, DOI 10.1002/j.1460-2075.1993.tb06171.x
[8]   THE ACTION OF BOTULINUM TOXIN ON THE NEURO-MUSCULAR JUNCTION [J].
BURGEN, ASV ;
DICKENS, F ;
ZATMAN, LJ .
JOURNAL OF PHYSIOLOGY-LONDON, 1949, 109 (1-2) :10-24
[9]  
COFFIELD JA, 1994, J BIOL CHEM, V269, P24454
[10]  
DasGupta BR, 1989, BOTULINUM NEUROTOXIN, P53